12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vyvanse lisdexamfetamine dimesylate: Phase III data

Top-line data from the identical, double-blind, international Phase III Study SPD489-343 and SPD489-344 in 383 and 390 patients aged 18-55 with moderate to severe binge eating disorder, respectively, showed that once-daily oral Vyvanse met the primary endpoint in both trials of reducing the number of binge eating days per week from baseline to weeks 11-12 vs. placebo (p<0.001). Vyvanse also met the secondary endpoints in both trials of improving CGI-I scores, 4-week binge cessation, body weight and Y-BOCS-BE scores vs. placebo...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >